Clinical Trials Logo

Respiratory Tract Infection clinical trials

View clinical trials related to Respiratory Tract Infection.

Filter by:

NCT ID: NCT05337163 Completed - Lung Cancer Clinical Trials

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Start date: February 25, 2022
Phase:
Study type: Observational

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose lung cancer by comparing with clinical standard method (includes chest CT examination or pathological examination).

NCT ID: NCT04424316 Completed - Clinical trials for Respiratory Tract Infection

A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.

Start date: June 17, 2020
Phase: Phase 3
Study type: Interventional

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the efficacy and safety of maternal immunization with RSVpreF against medically attended lower respiratory tract illness (MA-LRTI) in infants.

NCT ID: NCT04071158 Completed - Clinical trials for Respiratory Tract Infection

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

Start date: October 1, 2019
Phase: Phase 2
Study type: Interventional

This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age. This study will evaluate non-inferiority of RSV vaccine when given with Tdap and vice-versa.

NCT ID: NCT04032093 Completed - Clinical trials for Respiratory Tract Infection

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Start date: August 7, 2019
Phase: Phase 2
Study type: Interventional

This Phase 2b study will evaluate the safety, tolerability, and immunogenicity of an RSV vaccine in pregnant participants who receive either one of 2 dose levels of the vaccine, formulated with or without aluminum hydroxide, or placebo, and investigate safety and characteristics of antibodies in their infants.

NCT ID: NCT03572062 Terminated - Clinical trials for Respiratory Tract Infection

A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initial dose. In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62 subjects.

NCT ID: NCT03524118 Completed - Clinical trials for Respiratory Syncytial Virus

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Start date: September 20, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational age) and full-term (born at >35 weeks gestational age) infants. Participants will be randomized into 1 of 4 dose escalation panels (Panels A to D); an additional panel (Panel E) of full-term infants will receive the same dose as Panel D. Key safety and tolerability variables will be reviewed after each dose panel prior to administering the next-highest dose.

NCT ID: NCT02568800 Recruiting - Clinical trials for Urinary Tract Infection

Prolonged Infusion Cefepime and Nosocomial Infections

PICNIC
Start date: October 2015
Phase: Phase 3
Study type: Interventional

It is advocated that prolonged infusion of beta-lactamic antibiotics provides better bactericidal effect. The aim of the present study is to randomize patients a to extended cefepime infusion regimen (lasting four hours) or to a usual infusion regimen (not lasting more than thirty minutes) and evaluate the clinical efficacy of this theoretical pharmacokinetic advantage.

NCT ID: NCT02210156 Completed - Clinical trials for Respiratory Tract Infection

Effects of a Supplement on Acute Respiratory Infections

Start date: January 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether the consumption of a nutritional supplement with micronutrients and herbal extracts has an effect on the incidence of acute respiratory infections in susceptible adults. Our hypothesis is that subjects who consume the nutritional supplement will have a lower incidence and duration of acute respiratory infections in comparison with the placebo group.

NCT ID: NCT02087761 Active, not recruiting - Pneumonia Clinical Trials

A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients

Start date: December 2015
Phase: N/A
Study type: Observational

The ARIES Flu Assay is a real-time PCR based qualitative assay for the direct detection and differentiation of respiratory viral nucleic acid in nasopharyngeal swabs specimens. The objective of this study is to establish the diagnostic accuracy of ARIES Flu Assay.

NCT ID: NCT01789268 Completed - Clinical trials for Respiratory Tract Infection

Impact of Respiratory Pathogens in Infants

Start date: March 27, 2013
Phase:
Study type: Observational

This clinical study will investigate the relationships between sequential respiratory viral infections, patterns of intestinal and respiratory bacterial colonization, and adaptive cellular immune phenotypes which are associated with increased susceptibility to respiratory infections and long term respiratory morbidity in preterm and full term infants. This is a prospective, cohort study, enrolling at a single center via two sites (URMC and URMC-affiliated Highland Hospital and Rochester General Hospital). Enrollment will be accomplished in approximately 15 - 36 months. The study will enroll 280 subjects, 150 pre-term and 130 full-term.